辉瑞和BioNTech获得CHMP对LP.8.1 COVID-19疫苗的支持，对不断演变的SARS-CoV-2亚系提供增强的保护

2025-07-25 14:42

Data indicate that the LP.8.1-adapted COVID-19 vaccine confers improved immune response against currently dominant and emerging sublineages – including the XFG and NB.1.8.1 variants1 – compared to 2024-2025 COVID-19 vaccine formulations
Upon authorization by the European Commission (EC), the LP.8.1-adapted COVID-19 vaccine will be available for individuals 6 months of age and older
To date, over a billion adults and children around the world have received the Pfizer-BioNTech COVID-19 vaccine, which continues to demonstrate a favorable safety and efficacy profile supported by extensive real-world evidence, clinical, non-clinical, pharmacovigilance and manufacturing data
Doses will be ready to ship to applicable EU member states immediately upon authorization by the European Commission